Table 6.
Background of each patient group with rheumatoid arthritis in remission and nonremission.
| Variable | RA-rem | RA-nonrem | P-value |
|---|---|---|---|
| No. of cases | 107 | 53 | |
| Women | 102 (95.3) | 43 (81.1) | 1.269 × 10−1 |
| Age, yr | 73.8 ± 8.8 | 78.6 ± 8.1 | 5.499 × 10−2 |
| Past bone fragility fracture | 0 (0) | 6 (11.3) | <1.000 × 10−12 |
| osteoporosis drug administration | 69 (64.8) | 37 (67.9) | 9.134 × 10−1 |
| GCS administration | 10 (9.3) | 5 (9.4) | 8.573 × 10−1 |
| GCS dose, mg/day | 2.5 ± 1.2 | 2.7 ± 2.4 | 0.999 × 10−1 |
| Mean cumulative GCS dose, mg | 132.8 ± 134.0 | 148.5 ± 320.8 | 4.953 × 10−1 |
| number of comorbidities | 11.3 ± 3.9 | 11.5 ± 5.7 | 9.974 × 10−1 |
| Barthel Index | 78.0 ± 19.0 | 62.2 ± 26.3 | 2.543 × 10−2 |
| HAQ score in recent 6 months | 0.420 ± 0.650 | 1.040 ± 0.782 | 6.524 × 10−6 |
| DAS28-CRP in recent 6 months | 1.55 ± 0.34 | 2.99 ± 0.90 | <1.000 × 10−12 |
| Body mass index | 22.9 ± 2.8 | 21.1 ± 2.8 | 2.922 × 10−1 |
| Cr/CysC | 0.69 ± 0.13 | 0.67 ± 0.13 | 9.795 × 10−1 |
| BMD in LS, g/cm2 | 0.994 ± 0.179 | 0.938 ± 0.209 | 1.151 × 10−2 |
| BMD in FN, g/cm2 | 0.690 ± 0.122 | 0.627 ± 0.150 | 2.393 × 10−3 |
| BMD in TH, g/cm2 | 0.745 ± 0.122 | 0.686 ± 0.153 | 8.746 × 10−3 |
| BMD in GT, g/cm2 | 0.611 ± 0.121 | 0.594 ± 0.144 | 8.957 × 10−2 |
| BMD in LS after age and sex correction, %mean | 100.3 ± 18.5 | 96.9 ± 22.6 | 1.653 × 10−2 |
| BMD in FN after age and sex correction, %mean | 95.3 ± 16.1 | 89.3 ± 21.9 | 2.431 × 10−2 |
| BMD in TH after age and sex correction, %mean | 86.7 ± 14.8 | 80.3 ± 19.4 | 1.149 × 10−2 |
| BMD in GT after age and sex correction, %mean | 101.6 ± 17.4 | 93.6 ± 22.6 | 9.230 × 10−3 |
Values are presented as number (%) or mean ± standard deviation.
RA-rem, a RA patient group of whom clinical remission in past 6 months have been attained; RA-nonrem, a RA patient group of whom clinical remission in past 6 months could not attained; GCS, glucocorticoid steroid; HAQ, Health Assessment Questionnaire; DAS28-CRP, 28-joints disease activity score with C-reactive protein; Cr/CysC, serum creatinine to cystatin C ratio; BMD, bone mineral density; LS, lumbar spine; FN, femoral neck; TH, total hip; GT, greater trochanter.
RA-rem > RA-nonrem; in the RA-rem greater value is demonstrated than in the RA-nonrem. RA-rem < RA-nonrem; in the RA-rem smaller value is demonstrated than in the RA-nonrem. All the statistical procedures were performed with Mann-Whitney U -test. Statistical significance was set within 5%.